1. Home
  2. GIS vs GALT Comparison

GIS vs GALT Comparison

Compare GIS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GIS

General Mills Inc.

HOLD

Current Price

$47.00

Market Cap

24.9B

ML Signal

HOLD

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

HOLD

Current Price

$3.99

Market Cap

232.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GIS
GALT
Founded
1866
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.9B
232.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
GIS
GALT
Price
$47.00
$3.99
Analyst Decision
Hold
Strong Buy
Analyst Count
15
3
Target Price
$53.40
$8.50
AVG Volume (30 Days)
7.0M
794.2K
Earning Date
12-17-2025
11-14-2025
Dividend Yield
5.19%
N/A
EPS Growth
0.65
N/A
EPS
4.63
N/A
Revenue
$18,776,700,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$45.15
$0.84
52 Week High
$67.35
$7.13

Technical Indicators

Market Signals
Indicator
GIS
GALT
Relative Strength Index (RSI) 48.79 33.90
Support Level $46.45 $3.53
Resistance Level $49.25 $7.13
Average True Range (ATR) 0.79 0.63
MACD 0.05 -0.27
Stochastic Oscillator 44.57 12.78

Price Performance

Historical Comparison
GIS
GALT

About GIS General Mills Inc.

General Mills is a global packaged-food company that produces snacks, cereal, convenient meals, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Pillsbury, Betty Crocker, Blue Buffalo, and Haagen-Dazs. In fiscal 2025, 81% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. Although most of General Mills' products are sold through retail stores to consumers, the company also sells products to the foodservice channel and the commercial baking industry.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: